


Deliverable

Effective


Safe



Late Stent Thrombosis – Factors to Consider



Discontinuation Of Anti-Platelet Therapy Most Common Factor in Thrombosis Rate



Sources: Premature discontinuation from Milan/Siegburg Experience ACC 2005.
"Incidence, Predictors, and Outcomes of Thrombosis After Successful Implantation of Drug-Eluting Stents", Iakovou et al, JAMA, May 4, 2005



Premature Discontinuation of Anti-Platelet Therapy

“Premature Discontinuation of Anti-Platelet Therapy is the most important predictor of stent thrombosis after implantation”

Results:

- **At 9 month follow-up, 29 pts had stent thrombosis (1.3%).**
- **Among the 29 patients, 13 died (case fatality rate 45%).**

--Iakovou et al, JAMA May 2005*

Common reasons for discontinuation include:

- **Noncompliance**
- **Follow on procedures: surgery, dental, biopsies**
- **Resistance to clopidogrel, aspirin**


* “Incidence, Predictors, and Outcomes of Thrombosis After Successful Implantation of Drug-Eluting Stents”, Iakovou et al, JAMA, May 2005



Late Stent Thrombosis – Factors to Consider

“Of the 15 DES thrombosis cases, 6 (40%) were LST. This could be related to delayed stent endothelialisation, late stent malapposition...and even a localized sensitivity to the polymer.”

-- Moreno et al, Madrid, Spain (JACC 2005)



Late Incomplete Apposition in Endeavor Clinical Program

8 month results	EI* n=86	EII n=114	EIICA n=48	EIII n=190	Combined
Late Incomplete Apposition (%)	0	0	0	0.5 (1) [†]	0.2 (1)

* EI results at 12 months


† Thrombus at baseline resolved during Follow-up. No aneurismal remodeling



Late Stent Thrombosis from LIA


Case of LaST with Cypher Stent

44-year-old man was admitted with (AMI), 31 months after a initial SES placement




In Pre-Clinical Studies on Endeavor, Full Endothelialisation Was Achieved By 28 Days

Full endothelialisation achieved by 28 days with no aneurysms, incomplete apposition, medial necrosis, late thrombosis or filling defects




No Polymer Hypersensitivity

Acute Safety




- PC Biomimetic polymer
- Reduced platelet deposition

Late Safety



- Noninflammatory response and rapid endothelialisation†



- Smooth lumen and even neointimal distribution‡


†Full endothelialisation achieved by 28 days in preclinical study. Preclinical data on file at Medtronic, Inc.

‡Representative single Endeavor stent example from EII at 8 months

PC Technology is licensed under patents or patent applications owned by Biocompatibles



No Late Stent Thrombosis in More Than 1,200 pts



Defined as angiographic thrombus or subacute closure within the stented vessel at the time of the clinically driven angiographic restudy for documented ischaemia (chest pain and ECG changes). Any death not attributed to a non-cardiac cause within the first 30 days is considered a surrogate for stent thrombosis in the absence of documented angiographic stent patency.



Endeavor is DESigned for Safety

- **PC biomimetic polymer for reduced platelet deposition**
- **Non-inflammatory response and rapid endothelialisation**
- **No stent thrombosis after 10 days in over 1200 patients**

